中俄工业企业劳资关系比较研究:基于深度访谈

中俄两国都经历着从计划经济体制向市场经济体制转变的经济转型期,这种转型期造成两国企业在经营管理方面具有一定的共性.本文采用面对面访谈的方式,分别对中国和俄罗斯工业企业的管理者和蓝领工人进行调查,对两国工业企业劳资关系共同存在的问题提出了解决方案,对两国个别存在的问题进行了原因分析.     

对犯罪现场重建若干问题之探讨

犯罪现场重建以认知犯罪行为过程为目的,有相应的重建依据、重建步骤和工作原则。犯罪行为过程的重建以犯罪过程中的瞬间姿势和动作的重建为基础。犯罪现场重建的方法有几何学重建法、实验重演法和计算机模拟法。     

云南省11个民族腺苷脱氨酶(ADA)频率的分布调查

采用电泳技术对云南省汉、彝、自、傣、哈尼、瑶、布朗、基诺、拉祜、佤及苦聪等11个民族的ADA 进行了表型分布调查。并对-20℃、4℃、室温(20℃左右)保存的血痕ADA 活性进行了测定。在汉族人群中发现了一例ADA4-1稀有型,家系调查表明其是由父亲遗传下来的。     

应用判别分析法判断胸骨性别的研究

本文测量了85例国人胸骨(男52,女33)的全长、柄长、体长、柄最大宽、体最大宽、柄最大厚及体最大厚七个项目,发现所有项目都具有非常显著的性别差异,但两性间重迭率较高,用单项难以准确判定性别。为此,采用 Fisher 判别分析法建立了判定胸骨性别的判别函数,判别率最高达90%。考虑到残缺胸骨的性别鉴定,亦建立了相应的判别函数。与国外研究相比,本文方法判别率较高且更具有实用价值。     

应用PCR-SSCP技术检测PGM1基因型

目的应用PCR-SSCP技术分型PGM1基因型.方法提取156份武汉地区汉族无关个体的血样DNA,分别扩增PGM1基因外显子4和外显子8的多态性靶DNA,用SSCP分析PCR产物,判断基因型.结果两种PCR产物均检出了两个等位基因、三种基因型,DP值分别为0.5620、0.4405.综合外显子4和8的PCR-SSCP结果,分出8种PGM 1基因型,DP值为0.731 8.应用本法对保存10年的陈旧血痕和精斑PGM1分型成功.结论用PCR-SSCP分型PGM1基因型在法医物证检验中具有实用价值.     

Medical devices: reclassification and codification of the absorbable polydioxanone surgical suture. Final rule

The Food and Drug Administration (FDA) is announcing that it has issued an order in the form of a letter to Ethicon, Inc., reclassifying the absorbable polydioxanone surgical (PDS) suture intended for use in soft tissue approximation, including use in pediatric cardiovascular tissue where growth is expected to occur and ophthalmic surgery, from class III (premarket approval) to class II (special controls). Elsewhere in this issue of the Federal Register, FDA is announcing the availability of the guidance document entitled "Class II Special Controls Guidance Document: Surgical Sutures; Guidance for Industry and FDA," which is immediately in effect as the special control for the PDS suture, but remains subject to public comment and possible future revision under the agency's good guidance practices. The agency is reclassifying this device into class II because new information supplied by the petitioner indicates that special controls, in addition to general controls, will provide reasonable assurance of the safety and effectiveness of the device, and there is sufficient information to establish special controls. Accordingly, the order is being codified in the Code of Federal Regulations. Any firm submitting a premarket notification (510(k)) for a new PDS suture will need to address the issues covered in the special control guidance. However, the firm need only show that its device meets the recommendations of the guidance or in some other way provides equivalent assurances of safety and effectiveness.     

New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Final rule

The Food and Drug Administration (FDA) is amending its new drug and biological product regulations to allow appropriate studies in animals in certain cases to provide substantial evidence of the effectiveness of new drug and biological products used to reduce or prevent the toxicity of chemical, biological, radiological, or nuclear substances. This rule will apply when adequate and well-controlled clinical studies in humans cannot be ethically conducted and field efficacy studies are not feasible. In these situations, certain new drug and biological products that are intended to reduce or prevent serious or life-threatening conditions may be approved for marketing based on evidence of effectiveness derived from appropriate studies in animals and any additional supporting data.     

Technical revisions to medical criteria for determinations of disability. Final rules

These final rules make a number of technical revisions to the Listing of Impairments (the listings). We use the listings when you claim benefits based on disability under titles II and XVI of the Social Security Act (the Act). We are making these revisions to reflect advances in medical knowledge, treatment and terminology, to clarify certain criteria in the listings, to remove listings that we rarely use, and to add new listings consistent with current medical practice. We are making these individual technical revisions in order to improve our medical listings and make them easier to understand and use.